Payment overview · 2025
General Payments
$199.92
6 reported records · 3 companies
Healthcare provider profile · identity verified
Daniel Alfonso Ruiz-Soler, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · JUANA DIAZ, PR · NPI 1891754990
Verified facts
What the public records show
CMS Open Payments records show Daniel Alfonso Ruiz-Soler, M.D. received $199.92 in general payments during 2025 across 6 reported records.
AstraZeneca Pharmaceuticals LP accounted for 52.8% of that reported general-payment amount.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lokelma by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $105.46 | 52.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.30 | 25.7% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $43.16 | 21.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $199.92 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
120 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Famotidine | Famotidine | 822 | 131 |
| Atorvastatin Calcium | Atorvastatin Calcium | 749 | 245 |
| Gabapentin | Gabapentin | 623 | 130 |
| Omeprazole | Omeprazole | 392 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 360 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 357 | 112 |
| Losartan Potassium | Losartan Potassium | 356 | 129 |
| Pantoprazole Sodium | Pantoprazole Sodium | 349 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 285 | 61 |
| Simvastatin | Simvastatin | 280 | 85 |
| Metformin Hcl | Metformin Hcl | 255 | 69 |
| Lisinopril | Lisinopril | 244 | 72 |
| Fluticasone Propionate | Fluticasone Propionate | 241 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 233 | 75 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 215 | 66 |
| Synthroid | Levothyroxine Sodium | 198 | 52 |
| Alendronate Sodium | Alendronate Sodium | 197 | 46 |
| Nifedipine Er | Nifedipine | 194 | 58 |
| Clonazepam | Clonazepam | 191 | 34 |
| Glimepiride | Glimepiride | 176 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 57 |
| Montelukast Sodium | Montelukast Sodium | 173 | 30 |
| Carvedilol | Carvedilol | 169 | 63 |
| Clopidogrel | Clopidogrel Bisulfate | 166 | 53 |
| Finasteride | Finasteride | 150 | 32 |
| Temazepam | Temazepam | 134 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 127 | 31 |
| Fenofibrate | Fenofibrate | 125 | 40 |
| Furosemide | Furosemide | 123 | 40 |
| Farxiga | Dapagliflozin Propanediol | 120 | 26 |
| Allopurinol | Allopurinol | 117 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 108 | 22 |
| Sertraline Hcl | Sertraline Hcl | 100 | 19 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 98 | 17 |
| Trazodone Hcl | Trazodone Hcl | 98 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 95 | 37 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 94 | 32 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 93 | 22 |
| Latanoprost | Latanoprost | 93 | 18 |
| Eliquis | Apixaban | 81 | 30 |
| Buspirone Hcl | Buspirone Hcl | 80 | 11 |
| Donepezil Hcl | Donepezil Hcl | 79 | 24 |
| Meloxicam | Meloxicam | 79 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 78 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 77 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 21 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 75 | 19 |
| Alprazolam | Alprazolam | 74 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 74 | 13 |
| Glipizide | Glipizide | 72 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 72 | 25 |
| Doxazosin Mesylate | Doxazosin Mesylate | 70 | 21 |
| Baclofen | Baclofen | 67 | 31 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 66 | 14 |
| Trulicity | Dulaglutide | 66 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 65 | 12 |
| Tramadol Hcl | Tramadol Hcl | 63 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 62 | 11 |
| Jardiance | Empagliflozin | 60 | 18 |
| Humalog | Insulin Lispro | 58 | 20 |
| Prednisone | Prednisone | 58 | 40 |
| Meclizine Hcl | Meclizine Hcl | 57 | 18 |
| Memantine Hcl | Memantine Hcl | 57 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 19 |
| Sildenafil Citrate | Sildenafil Citrate | 56 | 13 |
| Sure Comfort | Syringe And Needle,insulin,1ml | 53 | 15 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 53 | 11 |
| Irbesartan | Irbesartan | 52 | 19 |
| Pregabalin | Pregabalin | 52 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 51 | 15 |
| Spironolactone | Spironolactone | 51 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 21 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 47 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 39 |
| Mirtazapine | Mirtazapine | 46 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 44 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | suppressed |
| Methotrexate | Methotrexate Sodium | 43 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 11 |
| Sure Comfort | Syring-Needl,disp,insul,0.3 Ml | 43 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 41 | suppressed |
| Ezetimibe | Ezetimibe | 41 | 13 |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 39 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | 11 |
| Lansoprazole | Lansoprazole | 37 | suppressed |
| Etodolac | Etodolac | 35 | 26 |
| Risperidone | Risperidone | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | 13 |
| Clotrimazole | Clotrimazole | 33 | 23 |
| Ibandronate Sodium | Ibandronate Sodium | 33 | suppressed |
| Nabumetone | Nabumetone | 32 | 15 |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Olanzapine | Olanzapine | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 28 | 12 |
| Atenolol | Atenolol | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | 17 |
| Chlorthalidone | Chlorthalidone | 25 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Lactulose | Lactulose | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Procto-Med Hc | Hydrocortisone | 24 | suppressed |
| Sulindac | Sulindac | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 11 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 24 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 23 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 22 | suppressed |
| Calcitriol | Calcitriol | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 19 | suppressed |
| Insulin Lispro | Insulin Lispro | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 18 | suppressed |
| Sure Comfort | Syringe-Needle,insulin,0.5 Ml | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 15 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 15 | 12 |
| Easy Touch | Syringe And Needle,insulin,1ml | 15 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 14 | suppressed |
| Levo-T | Levothyroxine Sodium | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Advocate Syringes | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 11 | suppressed |
| Potassium Chloride | Potassium Chloride | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $199.92 · 6 records | AstraZeneca Pharmaceuticals LP | — | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error